Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Parabilis Medicines (NASDAQ: PBLS), a clinical-stage biopharmaceutical company, announced the successful closing of its upsized IPO on June 11, 2026, raising $770.5 million in gross proceeds from 38.5 million shares at $20 per share, plus an additional $75 million from a concurrent private placement with Regeneron Pharmaceuticals. The company has raised over $1.2 billion in total funding in 2026 to support development of its proprietary Helicons™ therapeutic platform targeting undruggable protein targets.